Gross Profit Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Alkermes plc

Gross Profit Growth: Alnylam Pharmaceuticals vs. Alkermes

In the competitive landscape of biotechnology, Alnylam Pharmaceuticals and Alkermes plc have shown remarkable growth in gross profit over the past decade. From 2014 to 2023, Alnylam Pharmaceuticals experienced a staggering increase of over 2,900% in gross profit, starting from a modest $50 million to an impressive $1.5 billion. Meanwhile, Alkermes plc also demonstrated significant growth, with its gross profit rising by approximately 726%, from $171 million to $1.4 billion.

A Decade of Transformation

The data reveals a pivotal shift around 2020, where both companies saw substantial gains. Alnylam's gross profit surged by 70% from 2020 to 2021, while Alkermes saw a 22% increase in the same period. This trend underscores the dynamic nature of the biotech industry, where innovation and strategic investments drive financial success. As we look to the future, these companies are well-positioned to continue their upward trajectory.